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Pharmacological Studies of the
Involvement of Hypothalamic
Prostaglandins in the Regulation of
Thyrotropin Secretion
by Ken C. Wrightt and George A. Hedge*
A case is made for the involvement of pituitary prostaglandins (PGs) in the regulation of
thyrotropin (TSH) secretion by citing recent evidence that TSH release in vivo and in vitro is
enhanced by treatment with exogenous PGs and is inhibited by drugs (e.g., indomethacin) that
block PG synthesis. Pharmacological studies were then performed to test the hypothesis that
hypothalamic PGs also affect TSH secretion indirectly via the appropriate hypothalamic
hormones that regulate pituitary secretion. The inhibition of thyroidectomy-induced TSH
secretion was used as an endpoint in choosing the best ofseveral drugs purported to inhibit PG
synthesis. The established effectiveness ofindomethacin and aspirin were used for reference in
testing the following drugs: naproxen, mefenamic acid, tranylcypromine, and phenelzine. Only
naproxen was found to be effective, but since it was no more potent than indomethacin, the
latter drug was used for subsequent work. Indomethacin was stereotaxically implanted into
several hypothalamic regions known to regulate TSH secretion, and sequential plasma samples
were analyzed for TSH by radioimmunoassay. Bilateral implants of indomethacin in the
anterior hypothalamic area increased TSH secretion throughout the 72 hr period of study.
Sham inplants at this site and indomethacin implants in other nearby sites were ineffective.
These findings suggest that endogenous PGs play an inhibitory role in the hypothalamic
regulation of pituitary secretion.
Over the past couple of decades it has become
well recognized that the prostaglandins (PGs) can
exert a wide variety of endocrine and metabolic
effects. In particular, these ubiquitous fatty acids
have recently been shown to affect the secretion of
each ofthe hormones ofthe anterior pituitary gland
(1, 2). In some instances, the effects ofthe PGs are
direct ones in thatthey affect the pituitary itself. In
contrast, others ofthe known effects are indirect in
that they are exerted at the hypothalamus on
factors which in turn alter pituitary secretion.
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This presentation will address only one of the
pituitary hormones, thyrotropin or thyroid stimu-
lating hormone (TSH). There is by now consider-
able evidence from in vitro and invivo experiments
that certain PGs can enhance the secretion ofTSH
via a direct pituitary effect (3-6). In spite of some
rather small differences among the results just
cited, most of the available data indicate that the
direct stimulation of TSH secretion by the PGs
alone is relatively inconsequential. Instead, the
most striking effect of the PGs is their ability to
enhance pituitary responsiveness to thyrotropin
releasing hormone (TRH). This is illustrated in the
in vivo results presented in Figure 1. In these
experiments, various PGs and TRH (orappropriate
vehicles) were infused sequentially directly into the
anterior pituitaries of pentobarbital-anesthetized
female rats, and plasma samples were assayed for
TSH by radioimmunoassay.
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FIGURE 1. Potentiating effects of PGs on TRH-induced TSH
secretion. The 1 min PGinfusion (2 ,ug/2,ul) wasbegun at time
zero, the 30 sec TRH infusion (1 ng/1 ,ul) was begun at time
1.5 min, and blood samples were obtained at time 15 min.
None of the PG-saline values differs significantly from the
control. Reproduced with permission from Brown and Hedge
(4).
Having seen that exogenous PGs can affect TSH
secretion, the next logical question to pose was
whether or not endogenous PGs of the anterior
pituitary do affect TSH secretion. One approach to
this problem is to assess the secretion ofTSH under
conditions in which the availability ofpituitary PGs
has been limited by pharmacological blockade ofPG
synthesis. The diminution ofTSH secretion by such
treatment would provide evidence that the endoge-
nous PGs play some role in modulating normal TSH
secretion. Sundberg et al. (5) have provided some
such evidence from in vitro experiments, and we
have reported results of in vivo experiments that
support this hypothesis (7). For example, Figure 2
demonstrates that indomethacin (three subcutane-
ous injections of 3 mg each during the first 24 hr)
virtually abolishes the compensatory increase in
plasma TSH levels following surgical thyroidecto-
my. Similar results are seen when using aspirin
instead of the indomethacin, but higher doses are
required. It is also worth noting that the normal
riseinTSHis seenaftertheeffectoftheindomethacin
disappears, indicating that the effect is not due to
some type of irreversible tissue damage.
In contrast to the well documented pituitary
effects of PGs regarding TSH secretion, only few
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FIGURE 2. Plasma TSH and T4 levels following thyroidectomy
and indomethacin (Ind) orgelatin (GEL) treatment. Reproduced
with permission from Thompson and Hedge (1).
studies have investigated the possibility of an
indirect effect at some suprapituitary site. Our own
studies (4) and those of others (8) have indicated
that exogenous PGs injected into the medial basal
hypothalamus or lateral cerebral ventricles respec-
tively fail to alter plasma TSH levels. It was clear
from these studies that there is no significant effect
of any ofseveral prostaglandins even at a dose that
is 10-40 times greater than the dose ofPGE1 which
when injected in the same way will stimulate the
secretion of ACTH (9, 10). We were prepared to
accept the likelihood that PGs at the hypothalamic
level do not increase TSH secretion. However, the
fact that the mean TSH levels in all PG-treated
groups were numerically (though not significantly)
less than controls at least suggested that the PGs
might have an inhibitory effect which could not be
demonstrated optimally in the lower (i.e., basal)
portion ofthe secretory range. Wetherefore wanted
to design experiments which might be more appro-
priate to demonstrate such an inhibitory effect ifit
exists. First, we proposed to test the effects ofPGs
under conditions in which the hypothalamus is
actively stimulating TRH. In theory, this can be
achieved by exposure to a cold environment, by
electrical stimulation of the hypothalamus, or by
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sound, these approachs have led to a number of
practical problems such that we have favored a
different (and more successful) approach. If hypo-
thalamic PGs inhibit TSH secretion, then inhibition
of the synthesis of PGs would be expected to
increase TSH secretion. Such a result should be
easier to detect than the suppression ofbasal TSH
levels. By now, this pharmacological approach is
quite common in both in vitro and in vivo PG
studies, and it is the results of some of our
preliminary work of this sort that we will present
here.
Elsewhere in this issue we have presented re-
sults of experiments with enzymatically dispersed
pituitary cells in vitro that suggest that PGs
increase pituitary TSH secretion by acting at the
anterior pituitary. Those studies also made use of
pharmacological tools to demonstrate that endoge-
nous PGs play such arole. The technique we used in
that work offers numerous advantages in studying
the regulation of the pituitary's secretion, and the
dynamics ofits responses. However, the technique
is not as easily applicable to a study of the regula-
tion ofthe secretion ofthe hypothalamic hormones
which in turn regulate pituitary TSH secretion.
First, the cells ofthe hypothalamus, beingneurons,
cannot easily be dispersed enzymatically. The al-
ternative, incubating fragments of hypothalamic
tissue, is subject to all of the standard criticisms
related to the exchange of nutrients and metabo-
lites between medium and internal regions oftissue.
Other investigators (11) have been successful in
superfusing hypothalamic tissue "up stream" from
dispersed cells in studying ACTH secretion. How-
ever, our initial attempts to use this arrangement
for our studies ofTSH have resulted in very erratic
and short-lived release ofthe hypothalamic factors
regulating TSH secretion. Because ofthis, we have
chosen to investigate the possible roles ofhypotha-
lamic PGs in the regulation ofTSH using an in vivo
approach.
Indomethacin and aspirin are two of the more
common drugs used as experimental inhibitors of
PG synthesis, and we have found that both ofthese
drugs can inhibit TSH secretion by acting directly
at the pituitary (7). However, since the time that
we did those experiments, numerous other drugs-in
particular nonsteroidal antiinflammatory agents-
have also been shown to inhibit PG synthesis in
various biological systems (12, 13). Thus, it was of
interest to see if one or more ofthese drugs might
be significantly better than the indomethacin as an
experimental tool in our studies of hypothalamic
regulation of TSH secretion. We began by testing
selected drugs for their inhibition of thyroidectomy-
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FIGURE 3. Plasma TSH and T4 concentrations in thyroid-
ectomized rats treated with selected drugs known to inhibit
PGsynthesis. Drugs and doses (per 100gbodyweight) are as
follows: CONT, control injections of gelatin solution; NAP,
15 mg naproxen; MEF, 7.5 mg mefenamic acid; TRAN, 1.5
mg tranylcyromine sulfate; and PHEN, 0.015 mg phenelzine
sulfate. Thyroidectomy occurred at time zero.
induced TSH secretion. This rather simple protocol
was very appropriate for screening, and it very
clearly showed the effects of indomethacin and
aspirin in ourprevious studies. Based onthe known
potencies relative to indomethacin in other sys-
tems, we chose the following drugs at the doses
indicated in the legend of Figure 3: naproxen
(Naprosyn), mefenamic acid (Ponstel), tranylcy-
prominesulfate(Parnate), phenelzinesulfate(Nardil).
Female rats were thyroidectomized under ether
and injected sc at the indicated doses three times
over a 24 hr period as in the case of the earlier
studies with indomethacin and aspirin. Atthe times
indicated in Figure 3, blood samples were obtained
from tail veins under light ether anesthesia for
subsequent radioimmunoassay for TSH and T4. As
seen in the lower panel of Figure 3, only naproxen
inhibited thyroidectomy-induced TSH secretion (p
< 0.05 at 24 hr, and p < 0.01 at 96 hr). Each ofthe
other drugs tested in this series was without effect.
Before concluding that naproxen blocks TSH
secretion directly, it was necessary to show that
85FIGURE 4. Schematic parasagittal section of rat hypothalamus and pituitary with three squares superim-
posed at sites at which stereotaxic implants were made. Bilateral indomethacin implants were effective
only in the region of the open square in AHA. Abbreviations are as follows: FX, fornix; CA, anterior
commissure; POA, preoptic area; PVH, paraventricular nucleus; OC, optic chiasma; SC, suprachiasmatic
nucleus; AHA, anterior hypothalamic area; DMH, dorsomedial nucleus; VMH, ventromedial nucleus,
ARH, arcuate nucleus; PIT, pituitary; and P, pons.
the observed effect is not secondary to some change
in the rate at which T4is cleared after thyroidecto-
my. That is, it was possible that the drug could
increase the half-life of T4 resulting in plasma T4
levels that were higher than control during the
treatment and thus the lower TSH level might be
due to the normal function ofthe negative feedback
mechanism. This possibility is ruled out by the T4
data shown above the TSH data for the control and
naproxen groups at all times studied (Figure 3).
Even though naproxen has this inhibitory effect, it
is clearly no better than indomethacin in this
regard. Thus, we decided to use indomethacin in
oursubsequent study ofthe possible involvement of
hypothalamic PGs in regulating TSH secretion.
The systemic administration ofPGs ordrugs that
alter PG economy is acceptable for screening stud-
ies, but given the ubiquitous distribution of the
PGs, such a route of injection could result in
numerous side effects and thus yield data which are
virtually uninterpretable. With this in mind, we
chose to test forhypothalamic effects ofindomethacin
by stereotaxically implanting small amounts of it
(45 ,ug, or talc as control) into specific areas ofthe
hypothalamus known to be involved in the regula-
tion ofTRH and TSH secretion. In these studies, it
wasimperative thatwe administertheindomethacin
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locally since we already knew that the drug could
decrease pituitary responsiveness to TRH, and we
had to use plasma TSH as an endpoint in such
studies. These implants were made in pentobar-
bital-anesthetized (4.5 mg/100 g body weight) fe-
malerats. Subsequent blood samples wereobtained
by cardiac puncture under light ether anesthesia.
Figure 4 depicts diagramatically the areas of
interest in this experiment, and it indicates the
responsive and the unresponsive regions. Pilot
experiments involving single pellets on the midline
suggested that such implants might increase TSH
secretion, but the differences were not statistically
significant. However, when bilateral implants were
placed in the anterior hypothalamic area (centered
0.6 mm to each side of midline), significant in-
creases in TSH secretion were observed at alltimes
studied (Fig. 5). Controlimplants oftalc pellets had
no such effect. As would be expected the absolute
TSH concentrations at time zero (before implanta-
tion) in the two groups did not differ. Identical
implants ofindomethacin placed approximately one
mm anterior to this region (Fig. 4, cross-hatched
area) were without effect. Somewhat to our sur-
prise, such implants in the medial basal hypothala-
mus (Fig. 4, stippled area) were also withouteffect.
Although the latter region is definitely involved in
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FIGURE 5. Time course of stimulatory effect of indomethacin
(Ind) on plasma TSH levels. Bilateral implants of Ind were
made in the anterior hypothalamic area ofthe hypothalamus
at time zero. Statistical comparisons (paired t test) refer to
the time zero control samples taken just prior to implanta-
tion.
regulating TSH secretion, this result may be due to
the fact that this region primarily contains fibers
rather than cell bodies.
The results of ourearlier pharmacological studies
showing that indomethacin decreases TSH secre-
tion in response to stimulation by either TRH or
the removal of thyroid hormone feedback suggest
that anterior pituitary PGs enhance TSH secretion.
In contrast, the present results suggest that PGs of
the hypothalamus decrease TSH (presumably via
increasing TRH). These findings provide an inter-
esting contrast to the case of ACTH where it is
known that indomethacin in the hypothalamus
decreases stress-induced ACTH secretion (14),
whereas indomethacin in the anterior pituitary
increases ACTH responsiveness to a CRF prepara-
tion (15). In the latter case, it has also been shown
that the effect of indomethacin was due to its
limitingthe availability ofPGs since exogenous PGs
completely reversed this effect of the drug.
The overall picture that emerges regarding the
hypothalamic and pituitary effects of PGs on TSH
and ACTH secretion is depicted in Figure 6. In the
case of each of these tropic hormones, the effect of
the PGs at the pituitary is of opposite polarity to
the suprapituitary effect. It can also be seen that at
each anatomical level the effect ofthe PGs on TSH
is the opposite ofthe one on ACTH. Ofthe four PG
effects depected on Figure 6, all except the hypo-
thalamic inhibition ofTRH-TSH are now supported
both by studies with exogenous PGs and with
indomethacin or other PG synthetase inhibitors. As
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FIGURE 6. Diagram illustratingmultiple effects ofPGs onTSH
and ACTH secretion at both pituitary and hypothalamic
levels. A plus denotes stimulation, and a minus denotes
inhibition. Broken arrows signify blockade of the PG effect
by indomethacin (Ind).
far as we are aware, the present study with
indomethacin is the only one to have investigated
this hypothalamic involvement of PGs in TSH
secretion.
This reciprocity is reminiscent of the "inverse
relationship" often described regarding the regula-
tion ofthese two pituitary hormones (16). Although
this interaction was originally thought to be a
pituitary phenomenon, it has been suggested more
recently that the interaction may occur above the
pituitary. It is interesting to speculate that the
reciprocal effects ofthe prostaglandins could partic-
ipate in mediating such a relationship at either or
both of these levels.
The results of the present study are consistent
with the notion that some prostanoid can inhibit
TSH secretion by the pituitary indirectly by acting
in the region ofthe anterior hypothalamus. Howev-
er, to be accepted as firm evidence for this notion,
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known to be due to its inhibition of PG synthesis,
rather than to any of a host of other potential
effects of the drug. This distinction could be made
by experiments demonstrating that the addition of
exogenous PGs will reverse the effect ofthe drug.
Another aspect of the present work that requires
furtherattentionconcernsthefactthatindomethacin
blocks synthesis at a very early step (the cyclo-
oxygenase step), and thus prevents the production
of virtually all members ofthe prostaglandin fami-
ly. Although there was good reason to begin this
work with the pharmacological approach, the re-
sults obviously do not provide the identity of the
specific prostaglandin(s) that normally plays this
inhibitory role in the hypothalamus. However, this
information could also emanate from the experi-
ments just proposed, and would provide an impor-
tant confirmation of our interpretation of our pres-
ent results.
These studies were supported in part by U.S. Public Health
Service Grants AM-21348 and AM-07312.
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